Study of neuroblastoma cell characteristics and treatment outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather and analyze samples of neuroblastoma tissues, blood, and bone marrow from children diagnosed with high-risk neuroblastoma. Researchers will establish a biobank of these samples to facilitate laboratory studies focused on understanding the biology of neuroblastoma and improving treatment strategies. Clinical data, including treatment history and tumor characteristics, will also be collected to enhance the research efforts. The ultimate goal is to improve detection, measurement, and treatment response monitoring for neuroblastoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients must be greater than or 31 days of age.
* Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
* All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted.
* Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized.

Exclusion Criteria:

* There are no exclusion criteria on this study.

Where it's running

• Children's Hospital Los Angeles
  Los Angeles, California, United States Recruiting
• UCSF Helen Diller Family Comprehensive Cancer Center
  San Francisco, California, United States Recruiting
• Children Hospital of Colorado
  Aurora, Colorado, United States Recruiting
• AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
  Atlanta, Georgia, United States Recruiting
• University of Chicago, Comer Children's Hospital
  Chicago, Illinois, United States Recruiting
• Children's Hospital Boston
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Araz Marachelian, MD
• Email: amarachelian@chla.usc.edu
• Phone: 323-361-5687

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neuroblastoma patients' genomic and biological profile study

  This multicenter, prospective study tests profiles from blood, tumor tissue, and bone marrow to understand neuroblastoma in diagnosed, relapsed, or refractory patients.

  Recruiting at 35 sites Istituto Giannina Gaslini · Ancona and 34 other locations · NCT07881172

• CIML-NK Cells to Treat Neuroblastoma in Relapsed or Refractory Patients

  We’re testing whether donor-derived cytokine-induced memory-like NK cells can be safely given with dinutuximab to kids and young adults whose neuroblastoma has come back or not responded to treatment.

  Recruiting Phase 2 Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07635056

• Becotatug Vedotin for EGFR-positive relapsed, refractory, or metastatic pediatric solid tumors

  This trial will test Becotatug Vedotin, an EGFR-targeted antibody-drug conjugate, to see if it is safe and helps children aged 2–18 with EGFR-positive relapsed, refractory, or metastatic solid tumors.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT07584499

• Tracking tumor DNA over time in neuroblastoma

  This project tests whether regular blood tests measuring circulating tumor DNA and molecular residual disease can track disease status and detect relapse earlier in children with neuroblastoma.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT07516678

• Anti-GD2-800CW imaging to highlight neuroblastoma during surgery

  This trial will test whether a fluorescent antibody called anti-GD2-800CW can safely help surgeons see and remove neuroblastoma in children ages 1 to 18.

  Recruiting Phase 1/2 Princess Maxima Center for Pediatric Oncology · Utrecht · NCT07399821

• B7-H3 CAR T cells for relapsed or refractory solid tumors in children and young adults

  This study tests a new B7-H3 CAR T cell therapy to see if it is safe and can help kids and young adults whose solid tumors have come back or stopped responding to standard treatments.

  Recruiting Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07358260

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.